CureVac - Ingmar Hoerr, CEO
Added on 29 Mar 2017
Watched
3,315
times
CureVac, a clinical stage biopharmaceutical company from Tübingen, Germany, is pioneering the field of mRNA-based technology platforms for medical purposes with which mRNA is specifically optimised and formulated. Since 2000 the company develops novel mRNA-based cancer immunotherapies and prophylactic vaccines against infectious diseases – both under the brand RNActive®. CureVac has successfully established the first GMP (good manufacturing practice) facility worldwide for the manufacture of RNA and mRNA and has pioneered mRNA-based drugs in clinical studies.
코멘트
귀하의 계정에 아바타가 없습니다.
코멘트를 포스팅하기 위해서는 임시 아바타를 선택해야 합니다.
Confirm
에러가 발생했습니다. 다시 시도해주세요.
Or
Y8 계정으로 업로드
취소